Cite
HARVARD Citation
Tempero, M. et al. (n.d.). O-002Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. Annals of oncology. p. . [Online].